We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Developments in genomics have been rapidly altering the healthcare landscape by decoding the mysteries behind the function, structure, evolution, editing and mapping of genomes. Accordingly, growing demand for personalized medicine, solid investments and higher R&D activities will soon make genomics the next big thing in the investing space.
In fact, going by a MarketsandMarkets report, the $18.9-billion global genomics market is expected to reach $35.7 billion by 2024 at a CAGR of 13.5%. The report further states that North America accounted for the largest share of the global genomics market in 2018.
What’s Favouring the Genomic Testing Space?
The global genomics market has been favored by a streak of solid developments in sequencing, microarray, PCR (Polymerase Chain Reaction), Nucleic acid extraction and Purification techniques. Further, the implications of AI, cloud-based technologies and increased R&D focus have lent a competitive edge to the companies with significant exposure to genomics. Accordingly, the genomics market is seeing decreasing sequencing costs and widening genomics-based applications.
The genomics market is also seeing a ramp-up in government spending with a huge number of start-ups entering the market. Partnerships between research institutes and companies are also opening up new growth opportunities in the global genomics market. In March 2019, Illumina (ILMN - Free Report) collaborated with the Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen to study the relationship between the evolutionary history of certain mental and neurological disorders and infectious pathogens.
Tremendous progress is being observed within the gene editing space as well. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 gene editing is now being tested in early clinical trials for certain disorders like sickle cell disease, cystic fibrosis and Huntington’s disease. This development is taking place after six years of CRISPR technique’s first application to animals. However, a new advanced technique addressing the shortcomings of existing gene-editing platforms — SATI (intercellular linearized Single homology Arm donor mediated intron-Targeting Integration) — has been developed by the scientists at the Salk Institute.
ETFs to Gain From the Momentum
The above-mentioned trends have been benefiting genomics ETFs. Here we highlight a host of ETFs that investors can keep tabs on:
This is an actively managed ETF focusing on the companies likely to benefit from the extension and enhancement of the quality of human and other life by incorporating technological and scientific developments plus improvements and advancements in genomics into their business. The fund holds 39 stocks in its basket and has 0.75% in expense ratio. It has accumulated $428.1 million in its asset base (read: 5 Sector ETFs That Beat the Market in the First Half).
This fund follows the Dynamic Biotech & Genome Intellidex Index. The index comprises companies that are majorly engaged in the research, development, manufacturing and marketing plus distribution of various biotechnological products, services and processes and companies that gain significantly from scientific and technological advances in biotechnology and genetic engineering and research. The fund holds 29 stocks in its basket. It has managed $230 million in its asset base. Expense ratio comes in at 0.59% (read: Amgen to Buy Celgene's Otezla: 5 ETF Drugs).
This is a new entrant in the space having accumulated $15.1 million since its inception on Apr 5, 2019. It seeks to invest in companies that potentially stand to benefit from further advancements in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics and biotechnology. The product follows the Solactive Genomics Index, charging 68 bps in annual fees. It holds 41 stocks in its basket (read: Best June for Stocks in Decades: 5 Best ETFs).
iShares Genomics Immunology and Healthcare ETF (IDNA - Free Report)
This is another new entrant, which was launched in June 2019. Tracking the NYSE FactSet Global Genomics and Immuno Biopharma Index, the fund provides exposure to developed and emerging market companies that could gain from long-term growth and innovation in genomics, immunology and bioengineering. Holding a basket of 44 securities, the fund has an AUM of $23.2 million. It charges a fee of 47 basis points.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ETFs to Gain From the Booming Genomics Market
Developments in genomics have been rapidly altering the healthcare landscape by decoding the mysteries behind the function, structure, evolution, editing and mapping of genomes. Accordingly, growing demand for personalized medicine, solid investments and higher R&D activities will soon make genomics the next big thing in the investing space.
In fact, going by a MarketsandMarkets report, the $18.9-billion global genomics market is expected to reach $35.7 billion by 2024 at a CAGR of 13.5%. The report further states that North America accounted for the largest share of the global genomics market in 2018.
What’s Favouring the Genomic Testing Space?
The global genomics market has been favored by a streak of solid developments in sequencing, microarray, PCR (Polymerase Chain Reaction), Nucleic acid extraction and Purification techniques. Further, the implications of AI, cloud-based technologies and increased R&D focus have lent a competitive edge to the companies with significant exposure to genomics. Accordingly, the genomics market is seeing decreasing sequencing costs and widening genomics-based applications.
The genomics market is also seeing a ramp-up in government spending with a huge number of start-ups entering the market. Partnerships between research institutes and companies are also opening up new growth opportunities in the global genomics market. In March 2019, Illumina (ILMN - Free Report) collaborated with the Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen to study the relationship between the evolutionary history of certain mental and neurological disorders and infectious pathogens.
Tremendous progress is being observed within the gene editing space as well. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 gene editing is now being tested in early clinical trials for certain disorders like sickle cell disease, cystic fibrosis and Huntington’s disease. This development is taking place after six years of CRISPR technique’s first application to animals. However, a new advanced technique addressing the shortcomings of existing gene-editing platforms — SATI (intercellular linearized Single homology Arm donor mediated intron-Targeting Integration) — has been developed by the scientists at the Salk Institute.
ETFs to Gain From the Momentum
The above-mentioned trends have been benefiting genomics ETFs. Here we highlight a host of ETFs that investors can keep tabs on:
ARK Genomic Revolution Multi-Sector ETF (ARKG - Free Report)
This is an actively managed ETF focusing on the companies likely to benefit from the extension and enhancement of the quality of human and other life by incorporating technological and scientific developments plus improvements and advancements in genomics into their business. The fund holds 39 stocks in its basket and has 0.75% in expense ratio. It has accumulated $428.1 million in its asset base (read: 5 Sector ETFs That Beat the Market in the First Half).
Invesco Dynamic Biotechnology & Genome ETF (PBE - Free Report)
This fund follows the Dynamic Biotech & Genome Intellidex Index. The index comprises companies that are majorly engaged in the research, development, manufacturing and marketing plus distribution of various biotechnological products, services and processes and companies that gain significantly from scientific and technological advances in biotechnology and genetic engineering and research. The fund holds 29 stocks in its basket. It has managed $230 million in its asset base. Expense ratio comes in at 0.59% (read: Amgen to Buy Celgene's Otezla: 5 ETF Drugs).
Global X Genomics & Biotechnology ETF (GNOM - Free Report)
This is a new entrant in the space having accumulated $15.1 million since its inception on Apr 5, 2019. It seeks to invest in companies that potentially stand to benefit from further advancements in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics and biotechnology. The product follows the Solactive Genomics Index, charging 68 bps in annual fees. It holds 41 stocks in its basket (read: Best June for Stocks in Decades: 5 Best ETFs).
iShares Genomics Immunology and Healthcare ETF (IDNA - Free Report)
This is another new entrant, which was launched in June 2019. Tracking the NYSE FactSet Global Genomics and Immuno Biopharma Index, the fund provides exposure to developed and emerging market companies that could gain from long-term growth and innovation in genomics, immunology and bioengineering. Holding a basket of 44 securities, the fund has an AUM of $23.2 million. It charges a fee of 47 basis points.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>